New GSK WKN: A3DMB5 ISIN: GB00BN7SWP63 Forum: Aktien User: o2kuh

Sehr stark heute wieder…

+3%

25 €

+2,7%

24,8 €

+8%

24,3 €

Wenn das so weitergeht schaffen wir bald die 25€ 💪

23,71 EUR +5,03 % +1,14

Was hat sich da getan?

Seit Oktober extrem stark

💪

+3%

23,1 €

Total 2025 sales £32.7 billion +4% AER; +7% CER Specialty Medicines sales £13.5 billion (+17%); Respiratory, Immunology & Inflammation £3.8 billion (+18%); Oncology £2.0 billion (+43%); HIV sales £7.7 billion (+11%) Vaccines sales £9.2 billion (+2%); Shingrix £3.6 billion (+8%); Meningitis vaccines £1.6 billion (+12%); and Arexvy £0.6 billion (+2%) General Medicines sales £10.0 billion (-1%); Trelegy £3.0 billion (+13%) Total operating profit >100% and Total EPS >100% driven by lower Significant legal expenses, lower CCL charges and higher other operating income, partly offset by intangible asset impairments Core operating profit +11% and Core EPS +12% reflecting Specialty Medicines and Vaccines growth, SG&A productivity, higher royalty income and disciplined increased investment in R&D portfolio progression in Oncology and Vaccines Cash generated from operations of £8.9 billion with free cash flow of £4.0 billion Strong pipeline progress in 2025: 5 major FDA approvals: Blenrep, Exdensur, Nucala COPD, Penmenvy, Blujepa 7 pivotal trial starts including: risvutatug rezetecan (ris-rez) for 2L/3L ES-SCLC; efimosfermin in MASH; Exdensur for COPD; and velzatinib for 2L GIST Q4 2025 dividend of 18p declared; 66p FY 2025; 70p expected for full year 2026 £1.4 billion executed to date as part of the £2 billion share buyback programme announced at FY 2024 2026 guidance and 2031 sales outlook reaffirmed Expect 2026 turnover growth of between 3% to 5%; Core operating profit growth of between 7% to 9%; Core EPS growth of between 7% to 9% 2031 sales outlook of more than £40 billion

Nur kein Stress hier, das wird schon…